ArticleJAAD international2026

Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: Results from an early-terminated open-label trial.

Ravi Ramessur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.